Craig C. Hopkinson - 02 Mar 2026 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
02 Mar 2026
Net transactions value
-$267,485
Form type
4
Filing time
04 Mar 2026, 20:16:25 UTC
Previous filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopkinson Craig C. EVP R&D, Chief Medical Officer 900 WINTER STREET, WALTHAM /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson 04 Mar 2026 0001730048

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +5,000 +5.4% $19.34* 98,389 02 Mar 2026 Direct F1
transaction ALKS Ordinary Shares Sale $267,485 -9,000 -9.1% $29.72 89,389 02 Mar 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Employee Stock Option (Right to Buy) Options Exercise -5,000 -19% $0.000000* 21,356 02 Mar 2026 Ordinary Shares 5,000 $19.34 Direct F1, F4
transaction ALKS Employee Stock Option (Right to Buy) Award +83,037 $0.000000* 83,037 02 Mar 2026 Ordinary Shares 83,037 $30.25 Direct F5
transaction ALKS Restricted Stock Unit Award Award +38,568 $0.000000* 38,568 02 Mar 2026 Ordinary Shares 38,568 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4 These options are fully vested in accordance with their terms.
F5 Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027.
F6 Each restricted stock unit represents a contingent right to receive one ordinary share.
F7 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.